Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
AbCellera Biologics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABCL
Nasdaq
8731
https://www.abcellera.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for AbCellera Biologics Inc
AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
- Jan 24th, 2023 9:05 pm
Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock?
- Jan 24th, 2023 1:48 pm
AbCellera Biologics Clears Key Benchmark, Hitting 80-Plus RS Rating
- Jan 23rd, 2023 4:00 pm
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
- Jan 20th, 2023 12:00 am
Does AbCellera Biologics (NASDAQ:ABCL) Deserve A Spot On Your Watchlist?
- Jan 19th, 2023 4:59 pm
Strength Seen in Pliant Therapeutics, Inc. (PLRX): Can Its 8.3% Jump Turn into More Strength?
- Jan 12th, 2023 9:55 am
AbCellera Biologics Inc.'s (NASDAQ:ABCL) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
- Jan 5th, 2023 2:09 pm
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
- Jan 4th, 2023 9:05 pm
Trade Alert: The CEO, President & Chairperson Of AbCellera Biologics Inc. (NASDAQ:ABCL), Carl Hansen, Has Just Spent US$859k Buying A Few More Shares
- Dec 22nd, 2022 10:08 am
AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie
- Dec 16th, 2022 3:02 pm
AbCellera and AbbVie Partner to Advance New Antibody Therapies
- Dec 15th, 2022 12:00 pm
Is There An Opportunity With AbCellera Biologics Inc.'s (NASDAQ:ABCL) 43% Undervaluation?
- Dec 14th, 2022 1:18 pm
Implied Volatility Surging for AbCellera Biologics (ABCL) Stock Options
- Dec 12th, 2022 1:54 pm
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
- Dec 1st, 2022 12:00 pm
IBD Stock Of The Day AbCellera Is Pulling Back — Why Investors Should Be Paying Attention
- Nov 29th, 2022 9:10 pm
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022
- Nov 10th, 2022 1:05 pm
AbCellera Biologics Inc. (ABCL) Q3 2022 Earnings Call Transcript
- Nov 9th, 2022 4:00 am
AbCellera Biologics Inc. (ABCL) Q3 Earnings Miss Estimates
- Nov 8th, 2022 11:35 pm
AbCellera Reports Q3 2022 Business Results
- Nov 8th, 2022 9:05 pm
AbCellera to Present at Upcoming Investor Conferences in November
- Nov 4th, 2022 8:05 pm
Scroll